Biocon Launches Liraglutide in Netherlands with Pharmamedic B.V.
Filing Summary
Biocon Limited has launched its Glucagon-like Peptide-1 (GLP-1) product, Liraglutide, in the Netherlands through its partner, Pharmamedic B.V. The product will be marketed under the brand names Diavorin® for diabetes and Vobexoryn® for obesity. This launch follows approval from the Medicines Evaluation Board, Netherlands, marking Biocon’s first direct launch of Liraglutide in the European Union. The company aims to expand its GLP-1 portfolio in key global markets. The launch reflects Biocon’s commitment to providing affordable metabolic treatments and broadening access to advanced therapies.
Biocon Limited has announced the launch of its Glucagon-like Peptide-1 (GLP-1) product, Liraglutide, in the Netherlands. The product will be marketed under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management. The launch is facilitated through Biocon’s distribution partner, Pharmamedic B.V. This marks the first instance where Biocon will directly launch Liraglutide under its own brand in the European Union.
The financial terms of the agreement with Pharmamedic B.V. have not been disclosed in the filing. The focus remains on expanding Biocon’s GLP-1 portfolio across key global markets. The launch is part of Biocon’s strategy to enhance affordable access to complex therapies for chronic conditions.
The scope of the launch includes the distribution and marketing of Liraglutide in the Netherlands. The product is a synthetic analog of the GLP-1 peptide and is administered as a once-daily injection. It is used for the treatment of diabetes and obesity. The drug-device combination will be marketed under the brand names Diavorin® and Vobexoryn®. The approval from the Medicines Evaluation Board, Netherlands, was obtained earlier this year.
Biocon’s entry into the Netherlands market with Liraglutide is significant as it represents the company’s first direct launch of this product in the European Union. The launch aligns with Biocon’s strategic focus on peptide-based therapies and its commitment to broadening access to advanced therapies for diabetes and obesity. The company emphasizes its vertically integrated, end-to-end capabilities in delivering high-quality, affordable metabolic treatments.
The timeline for the launch was set following the approval from the Medicines Evaluation Board, Netherlands, earlier in the year. The launch is part of Biocon’s ongoing efforts to expand its presence in the European market. The company has partnered with Pharmamedic B.V., a leading supplier of generic drugs in the Dutch market, to facilitate the distribution and marketing of Liraglutide.
Pharmamedic B.V. is a national pharmaceutical company that focuses on sourcing high-quality generic medicines for the Dutch market. It specializes in unique and specialized products within niche segments and acts as a bridge between international manufacturers and Dutch healthcare providers.
Biocon Limited is an innovation-led global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets. Biocon also has a pipeline of promising novel assets in immunotherapy under development.